



How to Use This Document

This document is intended to summarize updates to the Wellfleet Rx National Preferred Formulary since the last formulary print version from 10/1/2020. These updates include both positive changes to existing formulary statuses and updates for newly approved medications. For all other medications not listed below, refer to the January 2021 National Preferred Formulary for information on formulary status.

**Positive Changes
Effective 1/1/2021 for All Users**

Move to Preferred Status

Multiple Sclerosis	AUBAGIO ZEPOSIA BAFIERTAM
Endocrine	CONTRACE
Hematological Disorders	FULPHILA
Inflammatory Disease	ENSPRYNG

Remove Prior Authorization

Oral Lipid Supplements	DOJOLVI
------------------------	---------

**Negative Changes
Effective 1/1/2021 for New Users
Effective 4/1/2021 for Existing Users**

Move to Excluded

Multiple Sclerosis	VUMERITY
--------------------	----------

Add Prior Authorization

Infectious Disease – Viral	DESCOVY
----------------------------	---------

Please note: The bolded medications are brands with a generic available.

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management



January 2021 Changes National Preferred Formulary

needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.